subject: Pwrm, Omex, Actg - Pennytobuck's Stock Report [print this page] PWRM, Power 3 Medical Products Inc., PWRM.OB
PWRM is a leader in bio-medical research and the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets.
PWRMs patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, drug targets, and its diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro).
PWRMs Products
PWRM continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS (Lou Gehrigs disease), Alzheimers, Parkinsons diseases, breast cancer, and drug resistance.
The NuroPro Blood Test is PWRMs diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system. The test involves monitoring the concentration of 59 proteins in blood serum to accurately detect and distinguish between Alzheimers disease, ALS (Lou Gehrigs disease), and Parkinsons disease .
PWRMs BC-SeraPro(TM) is a proteomic test for the diagnosis of breast cancer. This test is designed to measure the quantitative expression level of 22 protein biomarkers in the serum that differentiate between breast cancer patients and control subjects. The level of the biomarkers from the patients serum sample is compared to PWRMs patient database. Statistical analysis by linear discriminant function will analyze the biomarker levels of the patient sample and assign a probability score for the diagnosis. Probability score is ranged from 0.0 to 1.0. Results of PWRMs BC-SeraPro(TM) test should not be considered a stand alone diagnosis nor a guarantee and is intended to be used in conjunction with mammography and other accepted modalities.
PWRM expects to complete phase II clinical validation trials of its blood serum diagnostics for Alzheimers disease (NuroPro-AD), Parkinsons disease (NuroPro-PD) and breast cancer in 2010, followed by filings with the FDA.
The American Cancer Societys most recent estimates for breast cancer in the United States are for 2009: 192,370 new cases of invasive breast cancer and 40,170 deaths from breast cancer
Breast cancer is the most common cancer among women in the United States, other than skin cancer. It is the second leading cause of cancer death in women, after lung cancer. The chance of a woman having invasive breast cancer some time during her life is a little less than 1 in 8. The chance of dying from breast cancer is about 1 in 35.
Breast cancer death rates have been going down. This is probably the result of finding the cancer earlier and providing better treatment. Right now there are more than 2 million breast cancer survivors in the United States. (SOURCE: CLICK HERE)
Early detection of these diseases will allow physicians to intervene at an early stage to delay disease progression, potentially allowing patients to outlive their debilitating symptoms.
More about PWRM at www.power3medical.com
Acacia Research Corporation (Nasdaq:ACTG) announced that its subsidiary, WebMap Technologies LLC has entered into a settlement and license agreement with MapMyFitness, Inc. The agreement resolves litigation that was pending in the United States District Court for the Eastern District of Texas, Civil Action No. 2:09-CV-00343-DF-CE.
Odyssey Marine Exploration, Inc. (Nasdaq:OMEX), pioneers in the field of deep-ocean shipwreck exploration, filed a quarterly report with the Securities and Exchange Commission detailing results of the Company's second quarter 2010. For the second quarter of 2010, Odyssey reported revenue of $4.3 million, compared to $0.4 million in the second quarter 2009. The Company also reported a quarterly net loss of $3.5 million, compared to a net loss of $5.0 million in 2009. The net loss per share for the second quarter was $0.05, compared to a net loss of $0.09 per share in the second quarter 2009.
For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer (http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations.The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)
